BioVie Inc. (NASDAQ:BIVIW – Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totaling 20,933 shares, a drop of 51.6% from the September 15th total of 43,287 shares. Based on an average daily volume of 15,170 shares, the short-interest ratio is currently 1.4 days.
BioVie Stock Performance
Shares of BIVIW stock traded down $0.02 on Friday, hitting $0.24. The company had a trading volume of 238 shares, compared to its average volume of 54,968. BioVie has a twelve month low of $0.13 and a twelve month high of $0.79. The company has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.33.
BioVie Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and liver-related diseases. The company’s research programs are intended to address conditions associated with neuroinflammation, insulin resistance, chronic liver disease and complications of cirrhosis.
BioVie’s lead neurodegenerative disease candidate is bezisterim, also known as NE3107, an orally administered investigational therapy designed to cross the blood-brain barrier and modulate inflammatory signaling.
Featured Stories
- Five stocks we like better than BioVie
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
- Morgan Stanley Beats on Earnings, But Shares Fall on Trading Mix
- RTX Locks In a Decade of Defense Dominance
- Okeanis Riding Record Profits as Uncertainty Grows
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
